A3P

Log in

EU reinforces the control of medical devices

Medical devices such as prostheses and HIV tests will be subject to stricter controls in the EU under a new EU law, adopted in the wake of scandals such as the PIP breast prostheses.

Read more...

Ipsen completes the largest acquisition in its history

Ipsen Monday finalized the acquisition of Onivyde, flagship of the US biotech Merrimack Pharmaceuticals already indicated in metastatic pancreatic cancer, for which the French drugmaker would pay up to one billion dollars in total.

Read more...

Johnson and Johnson has successfully bid for Actelion

The US pharmaceutical giant Johnson and Johnson has successfully bid for the Swiss company Actelion, according to a statement released Friday by Actelion.

Read more...

Cancer: AstraZeneca sells the rights of Zoladex in North America

The British pharmaceutical company AstraZeneca announced Friday the sale of marketing rights in the United States and Canada, Zoladex, a treatment against cancers of the prostate and breast, to 250 million.

Read more...

Nosopharm raises EUR 2,4 million to develop a new antibiotic

The young Nosopharm pharmaceutical company said Tuesday it has raised € 2,4 million to help it develop a new class of antibiotics.

Read more...

a3p-100pxhaut logo

 fren

Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb here )


  group    administrators A3P
    
& Project Managers

letter   newsletter A3P